NAFLD and NASH pp 181-190 | Cite as

From Transcriptomic to Metabolomic in the Development of Biomarkers in NAFLD/NASH

  • George V. DedoussisEmail author
  • Athina I. Amanatidou


To date, several high-throughput omics have been advanced, such as transcriptomics, proteomics and metabolomics studies that aim to enlighten the complex nature behind NAFLD/NASH development. The sum up of all of these omics studies, identified candidate biomarkers that can be an effective tool in the diagnosis and treatment of NAFLD/NASH. The present chapter aims to provide a comprehensive outline of newly published biomarkers resulting from these studies.


NAFLD NASH NAFLD/NASH Biomarkers Transcriptomics Proteomics Metabolomics Omics 


  1. 1.
    Danford CJ, Yao ZM, Jiang ZG. Non-alcoholic fatty liver disease: a narrative review of genetics. J Biomed Res. 2018;32(5):389–400. Scholar
  2. 2.
    Younossi ZM, Blissett D, Blissett R, Henry L, Stepanova M, Younossi Y, et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology. 2016;64(5):1577–86. Scholar
  3. 3.
    Sookoian S, Pirola CJ. Personalizing care for nonalcoholic fatty liver disease patients: what are the research priorities? Pers Med. 2014;11(8):735–43. Scholar
  4. 4.
    Abd El-Kader SM, El-Den Ashmawy EM. Non-alcoholic fatty liver disease: the diagnosis and management. World J Hepatol. 2015;7(6):846–58. Scholar
  5. 5.
    Brunt EM, Wong VW, Nobili V, Day CP, Sookoian S, Maher JJ, et al. Nonalcoholic fatty liver disease. Nat Rev Dis Primers. 2015;1:15080. Scholar
  6. 6.
    Sookoian S, Pirola CJ. The genetic epidemiology of nonalcoholic fatty liver disease: toward a personalized medicine. Clin Liver Dis. 2012;16(3):467–85. Scholar
  7. 7.
    Benedict M, Zhang X. Non-alcoholic fatty liver disease: an expanded review. World J Hepatol. 2017;9(16):715–32. Scholar
  8. 8.
    Ginsburg GS, Phillips KA. Precision medicine: from science to value. Health Aff. 2018;37(5):694–701. Scholar
  9. 9.
    Quezada H, Guzman-Ortiz AL, Diaz-Sanchez H, Valle-Rios R, Aguirre-Hernandez J. Omics-based biomarkers: current status and potential use in the clinic. Boletin Medico del Hospital Infantil de Mexico. 2017;74(3):219–26. Scholar
  10. 10.
    Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology. 2010;52(5):1836–46. Scholar
  11. 11.
    Suppli MP, Rigbolt KTG, Veidal SS, Heeboll S, Eriksen PL, Demant M, et al. Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals. Am J Physiol Gastrointest Liver Physiol. 2019;316(4):G462–G72. Scholar
  12. 12.
    Pettinelli P, Arendt BM, Teterina A, McGilvray I, Comelli EM, Fung SK, et al. Altered hepatic genes related to retinol metabolism and plasma retinol in patients with non-alcoholic fatty liver disease. PLoS One. 2018;13(10):e0205747. Scholar
  13. 13.
    Zhang YJ, Hu Y, Li J, Chi YJ, Jiang WW, Zhang F, et al. Roles of microRNAs in immunopathogenesis of non-alcoholic fatty liver disease revealed by integrated analysis of microRNA and mRNA expression profiles. Hepatobiliary Pancreat Dis Int. 2017;16(1):65–79.CrossRefGoogle Scholar
  14. 14.
    Arendt BM, Comelli EM, Ma DW, Lou W, Teterina A, Kim T, et al. Altered hepatic gene expression in nonalcoholic fatty liver disease is associated with lower hepatic n-3 and n-6 polyunsaturated fatty acids. Hepatology. 2015;61(5):1565–78. Scholar
  15. 15.
    Atanasovska B, Rensen SS, van der Sijde MR, Marsman G, Kumar V, Jonkers I, et al. A liver-specific long noncoding RNA with a role in cell viability is elevated in human nonalcoholic steatohepatitis. Hepatology. 2017;66(3):794–808. Scholar
  16. 16.
    Pirola CJ, Fernandez Gianotti T, Castano GO, Mallardi P, San Martino J, Mora Gonzalez Lopez Ledesma M, et al. Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis. Gut. 2015;64(5):800–12. Scholar
  17. 17.
    Younossi ZM, Baranova A, Ziegler K, Del Giacco L, Schlauch K, Born TL, et al. A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease. Hepatology. 2005;42(3):665–74. Scholar
  18. 18.
    Niu L, Geyer PE, Wewer Albrechtsen NJ, Gluud LL, Santos A, Doll S, et al. Plasma proteome profiling discovers novel proteins associated with non-alcoholic fatty liver disease. Mol Syst Biol. 2019;15(3):e8793. Scholar
  19. 19.
    Rao PK, Merath K, Drigalenko E, Jadhav AYL, Komorowski RA, Goldblatt MI, et al. Proteomic characterization of high-density lipoprotein particles in patients with non-alcoholic fatty liver disease. Clin Proteomics. 2018;15:10. Scholar
  20. 20.
    Su W, Wang Y, Jia X, Wu W, Li L, Tian X, et al. Comparative proteomic study reveals 17beta-HSD13 as a pathogenic protein in nonalcoholic fatty liver disease. Proc Natl Acad Sci U S A. 2014;111(31):11437–42. Scholar
  21. 21.
    Dong S, Zhan ZY, Cao HY, Wu C, Bian YQ, Li JY, et al. Urinary metabolomics analysis identifies key biomarkers of different stages of nonalcoholic fatty liver disease. World J Gastroenterol. 2017;23(15):2771–84. Scholar
  22. 22.
    Mayo R, Crespo J, Martinez-Arranz I, Banales JM, Arias M, Minchole I, et al. Metabolomic-based noninvasive serum test to diagnose nonalcoholic steatohepatitis: results from discovery and validation cohorts. Hepatol Commun. 2018;2(7):807–20. Scholar
  23. 23.
    Papandreou C, Bullo M, Tinahones FJ, Martinez-Gonzalez MA, Corella D, Fragkiadakis GA, et al. Serum metabolites in non-alcoholic fatty-liver disease development or reversion; a targeted metabolomic approach within the PREDIMED trial. Nutr Metab. 2017;14:58. Scholar
  24. 24.
    Goffredo M, Santoro N, Trico D, Giannini C, D’Adamo E, Zhao H et al. A branched-chain amino acid-related metabolic signature characterizes obese adolescents with non-alcoholic fatty liver disease. Nutrients 2017;9(7).
  25. 25.
    Fisher CP, Kierzek AM, Plant NJ, Moore JB. Systems biology approaches for studying the pathogenesis of non-alcoholic fatty liver disease. World J Gastroenterol. 2014;20(41):15070–8. Scholar
  26. 26.
    Somvanshi PR, Venkatesh KV. A conceptual review on systems biology in health and diseases: from biological networks to modern therapeutics. Syst Synth Biol. 2014;8(1):99–116. Scholar
  27. 27.
    Sookoian S, Pirola CJ. Systems biology elucidates common pathogenic mechanisms between nonalcoholic and alcoholic-fatty liver disease. PLoS One. 2013;8(3):e58895. Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Biology/Biochemistry/Physiology Lab, Department of Nutrition Dietetics, School of Health Science and EducationHarokopio University of AthensAthensGreece

Personalised recommendations